GET DAILY SIGNALSAIM ImmunoTech (AIM) Stock Declines -15% Over 30 Days in Ongoing Downtrend
Key Takeaways
- AIM ImmunoTech shares fell about 15% over the past 30 days, sliding from roughly $0.18 in early October to near $0.155 by early November.
- The decline extends a broader downtrend: the stock is down approximately 43% over the past quarter and trades near the low end of its 52-week range of about $0.15 to $2.62.
- AIM remains a clinical-stage immuno-pharma company, and its near-term data catalyst, Phase 2 DURIPANC topline results, is not expected until the first quarter of 2027.
- On November 5, the company published a new investor presentation highlighting Ampligen’s potential to complement RAS-targeted therapies in pancreatic cancer, though the release did not reverse the slide.
- As a micro-cap with limited liquidity and ongoing operating losses, AIM carries above-average volatility and financial risk, including a previously disclosed going-concern note from its auditor.
- For additional detail, explore AIM’s Price Targets, Earnings, and Forecast pages for deeper data and analysis.
AIM ImmunoTech (AIM) Company Overview
AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida, focused on the research and development of immune-modulating therapies. Its lead asset, Ampligen (rintatolimod), is a double-stranded RNA molecule and highly selective Toll-like receptor 3 (TLR3) agonist being developed for oncology, viral diseases, and immune disorders. The company’s commercial portfolio also includes Alferon N Injection, a natural alpha interferon formulation approved in the United States and Argentina. Investors follow AIM primarily for its clinical pipeline, particularly the Phase 1/2 DURIPANC study evaluating Ampligen in combination with durvalumab in metastatic pancreatic cancer, alongside earlier-stage antiviral and biodefense programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, AIM declined roughly 15%, moving from a closing price near $0.18 in early October to about $0.155 in early November. The shares traded in a relatively narrow band through the period, touching a high near $0.19 and a low near $0.15, with no sustained recovery rally. The most recent quarter paints a steeper picture: from levels around $0.27 in early August, the stock has fallen approximately 43%. That quarterly decline followed a sharp, high-volume volatility spike in late August, after which the share price progressively gave back gains and continued to make lower lows. From what I see, this pattern aligns with the broader pressures on clinical-stage micro-caps.
Factors Behind the Recent 30-Day Decline
The 30-day decline was driven less by a single headline event than by persistent selling pressure on a thinly traded, clinical-stage micro-cap. Despite a steady stream of company communications—including updates on Ampligen’s pancreatic cancer strategy, media coverage of its antiviral potential, and a November 5 investor presentation on combining Ampligen with RAS-targeted therapies—none delivered a near-term catalyst sufficient to shift sentiment. With DURIPANC topline data not expected until early 2027, investors face a multi-month data gap, which can weigh on a stock with limited institutional sponsorship and modest daily trading volume. The lack of new clinical or financial data during the period left the shares vulnerable to continued downside drift.
Drivers of Performance Over the Past Quarter
The quarterly decline reflects a combination of fundamental and sentiment pressures. In early August, AIM reported second-quarter 2026 results showing a wider net loss and a bottom-line miss versus consensus, alongside a sharp rise in general and administrative expenses. The stock also experienced a brief, unusually high-volume spike in late August that quickly reversed, contributing to elevated volatility. Longer-term concerns include the company’s minimal revenue, ongoing cash burn, and a going-concern disclosure previously issued by its auditor. Meanwhile, the FDA approval of Revolution Medicines’ (RVMD) RAS-targeted therapy daraxonrasib reframed the competitive and scientific landscape in pancreatic cancer, which AIM has sought to position as complementary to its own Ampligen strategy.
Key Catalysts Ahead for AIM Stock
Looking ahead, the most significant catalyst for AIM is the Phase 2 DURIPANC topline readout, expected in the first quarter of 2027, followed by additional survival and quality-of-life analyses later in 2027. Investors should also monitor quarterly financial updates for cash position and operating expense trends, any new clinical or regulatory developments across Ampligen’s oncology, antiviral, and Long COVID programs, and further progress on the company’s intellectual-property and partnership efforts. Broader sentiment toward micro-cap and clinical-stage biotechnology, as well as the evolving pancreatic cancer treatment landscape shaped by emerging RAS-targeted therapies, will also influence how the stock trades in the months ahead. I’m watching this closely as the data gap narrows.
Exploring Automated Trading Approaches
In my own research process, I sometimes review Tickeron’s Trending AI Robots page to see how different algorithmic strategies are performing across the market. It provides a focused look at top bots without overwhelming detail, which can be useful when evaluating systematic ideas alongside fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AIM's RSI Indicator ascends from oversold territory
The RSI Indicator for AIM moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 36 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for AIM just turned positive on October 15, 2026. Looking at past instances where AIM's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +6.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where AIM advanced for three days, in 159 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
AIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AIM as a result. In 100 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AIM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.784) is normal, around the industry mean (3.498). P/E Ratio (-0.219) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.859) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. AIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders
Industry Biotechnology
Advertisement